Feb 01,2022

Rimidi Achieves 72% Revenue Growth, Grows Client Base by 141% in 2021

Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, today announced that the company increased its revenue by 72% and grew its client base by triple digits in 2021.

PRODUCT

#cgm

#bgm

View Analyst & Ambassador Comments
Go to original news
Feb 01,2022

How can we Speed Up Adoption of Digital Therapeutics?

The CEO and Co-founder of Fitterfly writes on how can we speed up adoption of digital therapeutics with examples from Fitterfly's Diabetes program.

View Analyst & Ambassador Comments
Go to original news
Feb 01,2022

BD Board of Directors Approves embecta Spinoff and Declares Distribution of embecta Stock

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has approved the planned spinoff of its diabetes care business, which will be known as Embecta Corp. ("embecta") and declared a pro rata distribution of all of the outstanding shares of embecta common stock to BD shareholders.

View Analyst & Ambassador Comments
Go to original news
Feb 01,2022

The Benefits of Utilizing Continuous Glucose Monitoring of Diabetes Mellitus in Primary Care: A Systematic Review

The study aims to show if CGM/is-CGM improves glycemic control, decreases rates of hypoglycemia, and improves staff/physician satisfaction in primary care. If so, what subgroups of patients with diabetes are most likely to benefit?

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 01,2022

Glooko Acquires Germany-Based xbird, A Medical AI Company

Glooko, Inc., a leading provider of remote patient monitoring and digital health solutions for diabetes and other chronic conditions announced it has acquired xbird, a Berlin-based health AI company developing JITAI (Just In Time Adaptive Intervention) technologies to support patients and their providers in predicting behavior and managing diabetes.

COLLABORATION MERGERS & ACQUISITION

#product & service

View Analyst & Ambassador Comments
Go to original news
Feb 02,2022

Patients Receiving Virta’s Diabetes Reversal Treatment See Sustained Reduction in Depressive Symptoms, New Research Shows

Virta Health , the leader in type 2 diabetes reversal, announced promising results on the impact of its diabetes reversal treatment on depressive symptoms. The research, published in The Journal of Behavioral Medicine , highlights rapid and sustained improvement in depressive symptoms during treatment, with nearly one-third fewer patients meeting the clinical cutoff for depression at two years.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 03,2022

BD REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal year 2022, which ended December 31, 2021.

View Analyst & Ambassador Comments
Go to original news
Feb 04,2022

Clinical Evaluation of a Novel Insulin Immunosensor

In this study, researchers sought to determine the accuracy of the novel insulin sensor and assess its therapeutic risk and benefit by presenting a new tool developed to indicate the potential therapeutic consequences arising from inaccurate insulin measurements.

CLINICAL STUDY

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 04,2022

One Drop Named To NYC Digital Health 100 By NYCHBL

One Drop, a leader in precision health solutions for people living with chronic conditions worldwide, announced it has been named to the NYC Digital Health 100 by New York City Health Business Leaders (NYCHBL), showcasing the most exciting and innovative startups in New York dedicated to transforming healthcare.

View Analyst & Ambassador Comments
Go to original news
Feb 07,2022

Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Elizabeth “Bess” Weatherman has been appointed to the Company’s Board of Directors.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES